[go: up one dir, main page]

ES2087038A1 - Nuevas piperidinas con actividad antagonista del paf. - Google Patents

Nuevas piperidinas con actividad antagonista del paf.

Info

Publication number
ES2087038A1
ES2087038A1 ES09402291A ES9402291A ES2087038A1 ES 2087038 A1 ES2087038 A1 ES 2087038A1 ES 09402291 A ES09402291 A ES 09402291A ES 9402291 A ES9402291 A ES 9402291A ES 2087038 A1 ES2087038 A1 ES 2087038A1
Authority
ES
Spain
Prior art keywords
antagonist activity
piperidine derivatives
paf antagonist
novel piperidine
paf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09402291A
Other languages
English (en)
Other versions
ES2087038B1 (es
Inventor
Elena Carceller
J Perre Jimenez
Nuria Recasens
Jordi Salas
Carmen Almansa
Javier Bartroli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09402291A priority Critical patent/ES2087038B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to PT95932668T priority patent/PT738269E/pt
Priority to CA002180660A priority patent/CA2180660C/en
Priority to ES95932668T priority patent/ES2147616T3/es
Priority to PCT/EP1995/003487 priority patent/WO1996014317A1/en
Priority to EP95932668A priority patent/EP0738269B1/en
Priority to AT95932668T priority patent/ATE192152T1/de
Priority to AU35636/95A priority patent/AU3563695A/en
Priority to US08/669,440 priority patent/US5705504A/en
Priority to MXPA/A/1996/002559A priority patent/MXPA96002559A/es
Priority to JP51497296A priority patent/JP4018137B2/ja
Priority to KR1019960703655A priority patent/KR100514201B1/ko
Priority to DE69516503T priority patent/DE69516503T2/de
Priority to DK95932668T priority patent/DK0738269T5/da
Publication of ES2087038A1 publication Critical patent/ES2087038A1/es
Priority to NO962855A priority patent/NO306345B1/no
Application granted granted Critical
Publication of ES2087038B1 publication Critical patent/ES2087038B1/es
Priority to GR20000401219T priority patent/GR3033528T3/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DE FORMULA I, DONDE M REPRESENTA 0,1 O 2; R1 REPRESENTA C1-4 ALQUILO; B REPRESENTA ZCR2R3-X-(CH2)N), CR2R3=CH- O R7N(Y)-CH2-; N REPRESENTA 0 O 1; X REPRESENTA NH O UN ENLACE SENCILLO; UNO DE R2 O R3 REPRESENTA C1-4 ALQUILO, C3-6 CICLOALQUILO O ARILO, Y EL OTRO REPRESENTA HIDROGENO, C1-4 ALQUILO, C1-4 HALOALQUILO, C3-6 CICLOALQUILO O ARILO; Z REPRESENTA HIDROGENO, C1-4 ALQUILO, (CH2-OR4, -COOR4 O -CONR4R5, Y CUANDO X REPRESENTA ENLACE SENCILLO, Z PUEDE SER TAMBIEN HIDROXI, (NR4R5, (NR6C(=O)OR4, -NR6C(=O)R4, -NR6C(=O)NR4R5, -N(OH)C(=O)NR4R5 O -NR6SO2R4; R4 REPRESENTA HIDROGENO, C1-4 ALQUILO, ARILO O ARIL-C1-4 ALQUILO; R5 Y R6 REPRESENTAN HIDROGENO O C1-4 ALQUILO; R7 REPRESENTA C1-4 ALQUILO, C3-6 CICIOALQUILO O ARILO; E Y REPRESENTA HIDROGENO, C1-4 ALQUILO, ARILO, ARIL-C1-4 ALQUILO, -C(=O)OR4, -C(=O)R4, -C(=O)NR4R5, O -SO2R4. ESTOS COMPUESTOS SON ANTAGONISTAS DEL PAF.
ES09402291A 1994-11-07 1994-11-07 Nuevas piperidinas con actividad antagonista del paf. Expired - Fee Related ES2087038B1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES09402291A ES2087038B1 (es) 1994-11-07 1994-11-07 Nuevas piperidinas con actividad antagonista del paf.
JP51497296A JP4018137B2 (ja) 1994-11-07 1995-09-05 Ｐａｆアンタゴニスト活性を有する新規ピぺリジン誘導体
ES95932668T ES2147616T3 (es) 1994-11-07 1995-09-05 Derivados de piperidina con actividad antagonista del paf.
PCT/EP1995/003487 WO1996014317A1 (en) 1994-11-07 1995-09-05 Novel piperidine derivatives with paf antagonist activity
EP95932668A EP0738269B1 (en) 1994-11-07 1995-09-05 Piperidine derivatives with paf antagonist activity
AT95932668T ATE192152T1 (de) 1994-11-07 1995-09-05 Piperidinderivate mit paf antagonistischer wirkung
AU35636/95A AU3563695A (en) 1994-11-07 1995-09-05 Novel piperidine derivatives with paf antagonist activity
US08/669,440 US5705504A (en) 1994-11-07 1995-09-05 Piperidine derivatives with PAF antagonist activity
PT95932668T PT738269E (pt) 1994-11-07 1995-09-05 Derivados de piperidina com actividade antagonista de paf
CA002180660A CA2180660C (en) 1994-11-07 1995-09-05 Novel piperidine derivatives with paf antagonist activity
KR1019960703655A KR100514201B1 (ko) 1994-11-07 1995-09-05 피에이에프길항활성을갖는피페리딘유도체
DE69516503T DE69516503T2 (de) 1994-11-07 1995-09-05 Piperidinderivate mit paf antagonistischer wirkung
DK95932668T DK0738269T5 (da) 1994-11-07 1995-09-05 Piperidinderivater med PAF-antagonistaktivitet
MXPA/A/1996/002559A MXPA96002559A (es) 1994-11-07 1995-09-05 Nuevos derivados de piperidina con actividadantagonista del paf
NO962855A NO306345B1 (no) 1994-11-07 1996-07-05 Piperidin-derivater med PAF antagonist-aktivitet, anvendelse derav og farmasöytisk blanding
GR20000401219T GR3033528T3 (en) 1994-11-07 2000-05-29 Novel piperidine derivatives with paf antagonist activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09402291A ES2087038B1 (es) 1994-11-07 1994-11-07 Nuevas piperidinas con actividad antagonista del paf.

Publications (2)

Publication Number Publication Date
ES2087038A1 true ES2087038A1 (es) 1996-07-01
ES2087038B1 ES2087038B1 (es) 1997-03-16

Family

ID=8287905

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09402291A Expired - Fee Related ES2087038B1 (es) 1994-11-07 1994-11-07 Nuevas piperidinas con actividad antagonista del paf.
ES95932668T Expired - Lifetime ES2147616T3 (es) 1994-11-07 1995-09-05 Derivados de piperidina con actividad antagonista del paf.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95932668T Expired - Lifetime ES2147616T3 (es) 1994-11-07 1995-09-05 Derivados de piperidina con actividad antagonista del paf.

Country Status (13)

Country Link
US (1) US5705504A (es)
EP (1) EP0738269B1 (es)
JP (1) JP4018137B2 (es)
KR (1) KR100514201B1 (es)
AT (1) ATE192152T1 (es)
AU (1) AU3563695A (es)
DE (1) DE69516503T2 (es)
DK (1) DK0738269T5 (es)
ES (2) ES2087038B1 (es)
GR (1) GR3033528T3 (es)
NO (1) NO306345B1 (es)
PT (1) PT738269E (es)
WO (1) WO1996014317A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4115522B2 (ja) * 1995-09-08 2008-07-09 ホタ． ウリアチ イ コンパニア ソシエダッド アノニマ 新規な５−アミノサリチル酸のアゾ誘導体
ES2165803B1 (es) * 2000-04-10 2003-09-16 Uriach & Cia Sa J Nueva sal de un derivado azo del acido 5-aminosalicilico
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
AU7931301A (en) * 2000-08-04 2002-02-18 Dmi Biosciences Inc Method of using diketopiperazines and composition containing them
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
PL2537524T3 (pl) 2003-05-15 2017-01-31 Ampio Pharmaceuticals, Inc. Leczenie chorób mediowanych przez komórki T
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008012524A1 (en) 2006-07-24 2008-01-31 Ucb Pharma S.A. Substituted aniline derivatives
KR100737397B1 (ko) 2007-01-31 2007-07-09 한국교세라정공(주) 밀링 커터
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
AU2012328605B9 (en) 2011-10-28 2017-08-03 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6723222B2 (ja) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284359A1 (en) * 1987-03-24 1988-09-28 Takeda Chemical Industries, Ltd. 1,4-Disubstituted piperazine compounds, their production and use
EP0441226A1 (en) * 1990-01-29 1991-08-14 J. URIACH & CIA. S.A. (cyanomethyl)pyridines useful as PAF antagonists
EP0528172A1 (en) * 1991-08-08 1993-02-24 J. URIACH & CIA. S.A. (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists
WO1993005042A1 (en) * 1991-09-04 1993-03-18 Minnesota Mining And Manufacturing Company 1-substituted 1h-imidazo(4,5-c)quinolin-4-amines; intermediate and pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) * 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
GB9102997D0 (en) * 1991-02-13 1991-03-27 Pfizer Ltd Therapeutic agents
US5283242A (en) * 1991-10-24 1994-02-01 American Home Products Corporation Substituted benzimidazoles and quinazolines as antihypertensives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284359A1 (en) * 1987-03-24 1988-09-28 Takeda Chemical Industries, Ltd. 1,4-Disubstituted piperazine compounds, their production and use
EP0441226A1 (en) * 1990-01-29 1991-08-14 J. URIACH & CIA. S.A. (cyanomethyl)pyridines useful as PAF antagonists
EP0528172A1 (en) * 1991-08-08 1993-02-24 J. URIACH & CIA. S.A. (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists
WO1993005042A1 (en) * 1991-09-04 1993-03-18 Minnesota Mining And Manufacturing Company 1-substituted 1h-imidazo(4,5-c)quinolin-4-amines; intermediate and pharmaceutical compositions

Also Published As

Publication number Publication date
DK0738269T5 (da) 2000-12-18
US5705504A (en) 1998-01-06
PT738269E (pt) 2000-08-31
NO306345B1 (no) 1999-10-25
DK0738269T3 (da) 2000-08-28
NO962855D0 (no) 1996-07-05
WO1996014317A1 (en) 1996-05-17
EP0738269A1 (en) 1996-10-23
ES2087038B1 (es) 1997-03-16
ES2147616T3 (es) 2000-09-16
DE69516503T2 (de) 2001-03-15
JPH09507862A (ja) 1997-08-12
JP4018137B2 (ja) 2007-12-05
DE69516503D1 (de) 2000-05-31
AU3563695A (en) 1996-05-31
MX9602559A (es) 1997-07-31
NO962855L (no) 1996-07-05
KR100514201B1 (ko) 2005-12-29
EP0738269B1 (en) 2000-04-26
ATE192152T1 (de) 2000-05-15
GR3033528T3 (en) 2000-09-29

Similar Documents

Publication Publication Date Title
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
NZ333801A (en) Piperidine and piperazine derivatives and their use as muscarinic antagonists
MY112102A (en) Therapeutic heterocycles.
PL308217A1 (en) Derivatives of 1-(oxo-acetyl)-piperidine-2-carboxylic as agents sensibilising multiple-drug-resistant cancer cells
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
IL114894A (en) Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
IL117149A0 (en) Muscarinic antagonists
DE69715865D1 (de) Muscarin-antagonisten
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
YU14196A (sh) Estri i amidi di-supstituisanog 1,4-piperidina, postupci za njihovo dobijanje i farmakološke kompozicije koje ih sadrže
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
ZA969621B (en) Therapeutic compounds
ATE201671T1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
IL117093A0 (en) Heterocyclic derivatives
GR3031215T3 (en) Bicyclic heterocycles as neurokinin a antagonists
DE69725457D1 (de) Piperazinderivate als neurokinin-antagonisten
PL323235A1 (en) Derivatives of piperazine as neurokinin antagonists
GR3032950T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
BG105923A (en) Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
GB9116056D0 (en) Compounds
CA2180660A1 (en) Novel piperidine derivatives with paf antagonist activity
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19941107

Kind code of ref document: A1

Effective date: 19941107

FD1A Patent lapsed

Effective date: 20051108